Beilstein Journal of Nanotechnology,
Journal Year:
2024,
Volume and Issue:
15, P. 1619 - 1626
Published: Dec. 16, 2024
Biomimetic
nanocarriers,
engineered
to
mimic
the
characteristics
of
native
cells,
offer
a
revolutionary
approach
in
treatment
various
complex
human
diseases.
This
strategy
enhances
drug
delivery
by
leveraging
innate
properties
cellular
components,
thereby
improving
biocompatibility
and
targeting
specificity.
nanocarriers
demonstrate
significant
advancements
systems
against
cancer
therapy,
Alzheimer's
disease,
autoimmune
diseases,
viral
infections
such
as
COVID-19.
Here,
we
address
therapeutic
applications
biomimetic
their
promising
for
personalized
medicine.
Journal of the Egyptian National Cancer Institute,
Journal Year:
2025,
Volume and Issue:
37(1)
Published: May 1, 2025
Extracellular
vesicles
(EVs)
have
emerged
as
key
cell-to-cell
communication
mediators
and
play
significant
roles
in
both
physiological
pathological
processes.
In
EVs,
exosomes
represent
a
distinct
subpopulation
of
EVs
that
been
found
to
be
involved
cancer
initiation
therapeutic
resistance.
Exosomes
transfer
diverse
spectrum
molecular
cargos
effects
on
the
tumor
microenvironment
(TME),
thereby
enabling
initiation,
metastasis,
recently
interest
therapy
due
their
role
important
treatment
The
exosomal
content-proteins,
miRNAs,
lncRNAs-allows
perform
functions
including
drug
efflux
detoxification,
cell
death
pathway
modulation,
induction
epithelial-to-mesenchymal
transition
(EMT),
suppression
immune
system.
addition
facilitating
stromal
interactions,
cause
extracellular
matrix
remodeling
induce
heterogeneity,
making
it
more
difficult
respond
therapy.
This
review
covers
intricate
resistance
with
regard
biogenesis,
content,
functional
impact
TME.
Along
this,
we
also
discuss
new
strategies
overcome
exosome-mediated
utilizing
exosome
inhibitors,
designed
therapy,
combination
conventional
therapies.
While
hold
promise
prediction
diagnosis
through
biomarker
function,
heterogeneous
origins
cryptic
make
target
interventions.
emphasizes
research
pathways
is
urgently
required
develop
can
improve
outcomes.
Inflammation and Regeneration,
Journal Year:
2024,
Volume and Issue:
44(1)
Published: Nov. 4, 2024
Abstract
Since
chimeric
antigen
receptor
T
(CAR-T)
cells
were
introduced
three
decades
ago,
the
treatment
using
these
has
led
to
outstanding
outcomes,
and
at
moment,
CAR-T
cell
therapy
is
a
well-established
mainstay
for
treating
CD19
+
malignancies
multiple
myeloma.
Despite
astonishing
results
of
in
B-cell-derived
malignancies,
several
bottlenecks
must
be
overcome
promote
its
safety
efficacy
broaden
applicability.
These
include
cumbersome
production
process,
concerns
viral
vectors,
poor
solid
tumors,
life-threatening
side
effects,
dysfunctionality
infused
over
time.
Exosomes
are
nano-sized
vesicles
that
secreted
by
all
living
play
an
essential
role
cellular
crosstalk
bridging
between
cells.
In
this
review,
we
discuss
how
existing
can
focusing
on
exosomes.
First,
delve
into
effect
tumor-derived
exosomes
function
inhibiting
their
secretion
enhance
therapy.
Afterward,
application
manufacturing
non-viral
approach
discussed.
We
also
review
latest
advancements
ex
vivo
activation
cultivation
exosomes,
as
well
potential
engineered
induction
or
boost
proliferation
Finally,
CAR-engineered
used
versatile
tool
direct
killing
tumor
delivering
intended
therapeutic
payloads
targeted
manner.
International Journal of Cancer,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 2, 2025
Abstract
Cancer
remains
one
of
the
leading
causes
death
worldwide.
Despite
remarkable
progress
in
prevention,
diagnosis,
and
therapy,
incidence
certain
types
cancer
persists,
urging
identification
clinically
relevant
biomarkers
development
novel
therapeutic
strategies
to
improve
clinical
outcomes
overcome
treatment
resistance.
Exosomes,
small
extracellular
vesicles
released
by
diverse
cells,
have
attracted
interest
biomedical
research
due
their
potential
as
carriers
for
different
treatments.
Moreover,
exosomes
play
a
pivotal
role
intercellular
communication,
modulating
various
cellular
processes.
One
those
is
autophagy,
pro‐survival
pathway
that
essential
human
cells.
Even
though
autophagy
traditionally
described
catabolic
route,
its
machinery
intricately
involved
responses,
including
vesicle
formation
secretion.
In
this
regard,
link
between
complex,
bidirectional,
highly
dependent
on
context.
Interestingly,
both
processes
been
extensively
implicated
pathogenesis,
highlighting
targets.
This
review
updates
our
understanding
how
can
participate
progression,
with
specific
focus
influence
tumor
growth,
angiogenesis,
metastasis.
Additionally,
interplay
these
minutely
reviewed
discussed,
we
hypothesize
crosstalk
may
hold
valuable
clues
biomarker
discovery
strategies.
Advanced Pharmaceutical Bulletin,
Journal Year:
2024,
Volume and Issue:
14(3), P. 634 - 645
Published: June 29, 2024
Purpose:
We
report
on
the
design
of
hypoxia-induced
dual-stage
acting
dendrimeric
nanoparticles
(NPs)
for
selective
delivery
two
chemotherapeutic
model
drugs
doxorubicin
(DOX)
and
tirapazamin
(TPZ)
deepened
drug
into
hypoxic
tumors
in
vitro.
Methods:
PAMAM
G5
dendrimers
were
crosslinked
with
a
azo
linker,
attached
to
mPEG
form
detachable
corona
dendrimer
surface
(PAP
NPs).
NPs
characterized
by
Zeta
sizer,
transmission
electron
microscope
(TEM),
Fourier
transforms
infrared
(FTIR)
release
kinetics.
The
anti-cancer
performance
PAPs
was
evaluated
numerous
tests
2D
3D
cultured
MDA-MB-231
breast
cancer
cells.
Results:
MTT
assay
showed
significant
difference
between
PAP
PAMAMG5
terms
biocompatibility,
effect
PAP@DOX
significantly
greater
than
free
DOX
conditions.
results
DAPI
Annexin
V-FITC/PI
cell
staining
also
confirmed
uniform
penetration
as
validated
induction
90%
apoptosis
spheroids
high
level
PAP@DOX-induced
ROS
generation
under
hypoxia
Mechanistically,
reduced
expression
mTOR,
Notch1,
while
Bax
Caspase3
considerably
unregulated,
compared
controls.
Importantly,
hypoxia-responsive
disintegration
activation
HAP
synergized
promote
deep
homogenous
distribution
whole
microtumor
regions
efficiently
eliminate
residual
tumor
Conclusion:
Our
indicate
safety
therapeutic
potential
system
targeted
chemotherapeutics
particular
HAPs
which
show
maximum
activity
against
solid
tumors.
Beilstein Journal of Nanotechnology,
Journal Year:
2024,
Volume and Issue:
15, P. 1619 - 1626
Published: Dec. 16, 2024
Biomimetic
nanocarriers,
engineered
to
mimic
the
characteristics
of
native
cells,
offer
a
revolutionary
approach
in
treatment
various
complex
human
diseases.
This
strategy
enhances
drug
delivery
by
leveraging
innate
properties
cellular
components,
thereby
improving
biocompatibility
and
targeting
specificity.
nanocarriers
demonstrate
significant
advancements
systems
against
cancer
therapy,
Alzheimer's
disease,
autoimmune
diseases,
viral
infections
such
as
COVID-19.
Here,
we
address
therapeutic
applications
biomimetic
their
promising
for
personalized
medicine.
